Clinical Trials
46 trialsResimmune®
Virogen Biotechnology Inc.
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
TELLOMAK
Innate Pharma
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
CurbMF
Virogen Biotechnology Inc.
FLASH2
Soligenix
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Soligenix
RESMAIN
4SC AG
IMAGINE
Myeloid Therapeutics
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Soligenix
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
Genmab
CTCL
OncoSec Medical Incorporated
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
Genmab
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara Biotherapeutics
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Elorac, Inc.
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Sorrento Therapeutics, Inc.
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Soligenix
SOLAR
miRagen Therapeutics, Inc.
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
4SC AG
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Novartis
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Novartis
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
AbbVie
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
Moleculin Biotech, Inc.
ALCANZA
Takeda
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
miRagen Therapeutics, Inc.
PRISM
miRagen Therapeutics, Inc.
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Bausch Health Americas, Inc.
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)
Neumedicines Inc.
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Merck Sharp & Dohme LLC
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Virogen Biotechnology Inc.
Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
TetraLogic Pharmaceuticals
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
Progen Pharmaceuticals
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Morphotek
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
Valerio Therapeutics
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
Yaupon Therapeutics
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
Yaupon Therapeutics
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Emergent Product Development Seattle LLC
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
BioCryst Pharmaceuticals
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Eisai Inc.
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
Eisai Inc.